
Kate D Sutherland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5962367/publications.pdf Version: 2024-02-01



KATE D SUTHERIAND

#	Article	IF	CITATIONS
1	Absence of pro-survival A1 has no impact on inflammatory cell survival in vivo during acute lung inflammation and peritonitis. Cell Death and Differentiation, 2022, 29, 96-104.	11.2	7
2	Killing SCLC: insights into how to target a shapeshifting tumor. Genes and Development, 2022, 36, 241-258.	5.9	26
3	Glutaminase inhibition impairs CD8 TÂcell activation in STK11-/Lkb1-deficient lung cancer. Cell Metabolism, 2022, 34, 874-887.e6.	16.2	55
4	Delineating the roles of Grhl2 in craniofacial development through tissueâ€specific conditional deletion and epistasis approaches in mouse. Developmental Dynamics, 2021, 250, 1191-1209.	1.8	2
5	Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. Translational Lung Cancer Research, 2021, 10, 2788-2805.	2.8	3
6	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell, 2020, 37, 37-54.e9.	16.8	138
7	Characterization of a novel human BFL-1-specific monoclonal antibody. Cell Death and Differentiation, 2020, 27, 826-828.	11.2	2
8	Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis. Cell Death and Disease, 2020, 11, 877.	6.3	7
9	NOTCH Your Usual Suspect: MYC Charged with Controlling Neuroendocrine Cell-Fate in Small Cell Lung Cancer. Cancer Cell, 2020, 38, 17-20.	16.8	3
10	Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy. European Journal of Immunology, 2020, 50, 1871-1884.	2.9	6
11	Harnessing Natural Killer Immunity in Metastatic SCLC. Journal of Thoracic Oncology, 2020, 15, 1507-1521.	1.1	50
12	Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma. Oncogene, 2020, 39, 5177-5186.	5.9	5
13	Balancing the Count: Harmonizing Panel-Based Tumor Mutational Burden Assessment. Journal of Thoracic Oncology, 2020, 15, 1106-1109.	1.1	1
14	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	1.1	119
15	Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nature Communications, 2019, 10, 4190.	12.8	73
16	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell, 2019, 36, 385-401.e8.	16.8	359
17	Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. Cell Metabolism, 2018, 27, 935-943.e4.	16.2	167
18	Combining Cell Type-Restricted Adenoviral Targeting with Immunostaining and Flow Cytometry to Identify Cells-of-Origin of Lung Cancer. Methods in Molecular Biology, 2018, 1725, 15-29.	0.9	9

KATE D SUTHERLAND

#	Article	IF	CITATIONS
19	Lung morphogenesis is orchestrated through Grainyhead-like 2 (Grhl2) transcriptional programs. Developmental Biology, 2018, 443, 1-9.	2.0	21
20	"Keaping―a lid on lung cancer: the Keap1-Nrf2 pathway. Cell Cycle, 2018, 17, 1696-1707.	2.6	39
21	FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. Oncogene, 2018, 37, 6096-6104.	5.9	10
22	Lung Basal Stem Cells Rapidly Repair DNA Damage Using the Error-Prone Nonhomologous End-Joining Pathway. PLoS Biology, 2017, 15, e2000731.	5.6	37
23	SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin. Cancer Cell, 2016, 30, 519-532.	16.8	178
24	The LIM-domain only protein 4 contributes to lung epithelial cell proliferation but is not essential for tumor progression. Respiratory Research, 2015, 16, 67.	3.6	6
25	Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis. Genes and Development, 2015, 29, 1587-1592.	5.9	63
26	Cellular Mechanisms Underlying Intertumoral Heterogeneity. Trends in Cancer, 2015, 1, 15-23.	7.4	36
27	Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4952-4957.	7.1	205
28	Rapid target gene validation in complex cancer mouse models using reâ€derived embryonic stem cells. EMBO Molecular Medicine, 2014, 6, 212-225.	6.9	78
29	Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult Mouse Lung. Cancer Cell, 2011, 19, 754-764.	16.8	428
30	Cell of origin of lung cancer. Molecular Oncology, 2010, 4, 397-403.	4.6	153